These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 26253488)

  • 1. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events.
    Songthong AP; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
    Radiat Oncol; 2015 Aug; 10():166. PubMed ID: 26253488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.
    Lertbutsayanukul C; Prayongrat A; Kannarunimit D; Chakkabat C; Netsawang B; Kitpanit S
    Strahlenther Onkol; 2018 May; 194(5):375-385. PubMed ID: 29302704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of adaptive two-step intensity-modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (JCOG1015).
    Nishimura Y; Ishikura S; Shibata T; Kodaira T; Ito Y; Tsuchiya K; Murakami Y; Saitoh JI; Akimoto T; Nakata K; Yoshimura M; Teshima T; Toshiyasu T; Ota Y; Ishikawa K; Shimizu H; Minemura T; Nakamura K; Hiraoka M
    Int J Clin Oncol; 2020 Jul; 25(7):1250-1259. PubMed ID: 32221802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma.
    Tao CJ; Liu X; Tang LL; Mao YP; Chen L; Li WF; Yu XL; Liu LZ; Zhang R; Lin AH; Ma J; Sun Y
    Chin J Cancer; 2013 Oct; 32(10):525-32. PubMed ID: 24016394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma.
    Yi J; Huang X; Gao L; Luo J; Zhang S; Wang K; Qu Y; Xiao J; Xu G
    Radiat Oncol; 2014 Feb; 9():56. PubMed ID: 24533569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
    Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
    Lee N; Harris J; Garden AS; Straube W; Glisson B; Xia P; Bosch W; Morrison WH; Quivey J; Thorstad W; Jones C; Ang KK
    J Clin Oncol; 2009 Aug; 27(22):3684-90. PubMed ID: 19564532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute toxicity in nasopharyngeal carcinoma patients treated with IMRT/VMAT.
    Ozdemir S; Akin M; Coban Y; Yildirim C; Uzel O
    Asian Pac J Cancer Prev; 2015; 16(5):1897-900. PubMed ID: 25773841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
    Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
    Han L; Lin SJ; Pan JJ; Chen CB; Zhang Y; Zhang XC; Liao XY; Chen QS
    Chin J Cancer; 2010 Feb; 29(2):145-50. PubMed ID: 20109341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer.
    Vlacich G; Stavas MJ; Pendyala P; Chen SC; Shyr Y; Cmelak AJ
    Radiat Oncol; 2017 Jan; 12(1):13. PubMed ID: 28086954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
    Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
    Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMRT with simultaneous integrated boost and concurrent chemotherapy for nasopharyngeal cancer: plan evaluation and treatment outcome.
    Kim JW; Cho JH; Keum KC; Kim JH; Kim GE; Lee JY; Kim SK; Lee CG
    Jpn J Clin Oncol; 2012 Dec; 42(12):1152-60. PubMed ID: 23077243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
    Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Kim K; Wu HG; Kim HJ; Sung MW; Kim KH; Lee SH; Heo DS; Kim HJ; Park CI
    Head Neck; 2009 Sep; 31(9):1121-8. PubMed ID: 19340863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiotherapy (IMRT)/Tomotherapy following neoadjuvant chemotherapy in stage IIB-IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): a mono-institutional experience.
    Franchin G; Vaccher E; Talamini R; Politi D; Gobitti C; Minatel E; Lleshi A; Sartor G; Mascarin M; Rumeileh IA; Trovò MG; Barzan L
    Oral Oncol; 2011 Sep; 47(9):905-9. PubMed ID: 21783403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
    Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
    JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
    You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
    Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma.
    Zhang L; Shan GP; Li P; Cheng PJ
    Med Oncol; 2015 Mar; 32(3):41. PubMed ID: 25631634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.